- Home
- LIQT vs OSRH Comparison
LIQT vs OSRH Comparison
Compare LIQT & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LIQT | OSRH |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Denmark | United States |
| Employees | N/A | 21 |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 11.4M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | LIQT | OSRH |
|---|---|---|
| Price | $1.51 | $0.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.30 | N/A |
| AVG Volume (30 Days) | 11.5K | ★ 457.5K |
| Earning Date | 05-13-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.12 | N/A |
| Revenue Next Year | $63.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.34 | $0.38 |
| 52 Week High | $3.35 | $3.30 |
Technical Indicators
Market Signals| Indicator | LIQT | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 44.15 |
| Support Level | $1.41 | $0.39 |
| Resistance Level | $1.97 | $0.47 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 65.28 | 23.28 |
Price Performance
Historical ComparisonAbout LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in businesses that are liquid filtration market and the silicon carbide ceramic membrane & diesel particulate filter (DPF) market. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and others. Its operating segment includes Water, Ceramics, and Plastics.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.